Insider · CIK 0002092017
Jeegar Pravinkumar Patel
Files at EVMN (Evommune, Inc.). First filing Jun 3, 2026, latest Jun 24, 2026.
In brief
Jeegar Pravinkumar Patel files SEC Form 4 as officer at EVMN (Evommune, Inc.). Since Jun 3, 2026, Jeegar Pravinkumar Patel has reported 0 open-market buys worth $0 and 2 open-market sells worth $413k, the latest filed on Jun 24, 2026.
A track record needs three past buys with six months of prices behind them; Jeegar Pravinkumar Patel has 0, so none is measured yet.
The newest scored trade: sold $33k of EVMN on Jun 22, 2026, filed Jun 24, 2026, scored 1 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $413k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
EVMN: Evommune, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 1Weak | Evommune, Inc. | $33k 1,488 shares | -3% | +50% from low-29% from high | |
| 21Weak | Evommune, Inc. | $379k 16,687 shares | -26% | +48% from low-30% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 1, 2026 | EVMN Evommune, Inc. | 18,175 0.05% of outstanding | $422k | Jun 1, 2026 | none |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | EVMN Evommune, Inc. | MOption exercise Common Stock10b5-1 | +1,488 | $3.84 | $5,714 | 47,891 | Jun 24, 2026 |
| Jun 22, 2026 | EVMN Evommune, Inc. | SOpen-market sale Common Stock10b5-1 | -1,488 | $22.50 | $33k | 46,403 | Jun 24, 2026 |
| Jun 22, 2026 | EVMN Evommune, Inc. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -1,488 | $0.00 | $0 | 27,842 | Jun 24, 2026 |
| Jun 1, 2026 | EVMN Evommune, Inc. | MOption exercise Common Stock10b5-1 | +13,512 | $3.84 | $52k | 63,090 | Jun 3, 2026 |
| Jun 1, 2026 | EVMN Evommune, Inc. | SOpen-market sale Common Stock10b5-1 | -16,687 | $22.74 | $379k | 46,403 | Jun 3, 2026 |
| Jun 1, 2026 | EVMN Evommune, Inc. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -13,512 | $0.00 | $0 | 29,330 | Jun 3, 2026 |
| Apr 16, 2026 | EVMN Evommune, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +69,315 | $0.00 | $0 | 69,315 | Apr 17, 2026 |
| Dec 9, 2025 | EVMN Evommune, Inc. | FTax withholding Common Stock | -7,513 | $17.84 | $134k | 49,578 | Dec 11, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Common Stock | +3,175 | - | - | 57,091 | Nov 12, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Series B Preferred Stockderivative | -25,000 | - | - | 0 | Nov 12, 2025 |
| Nov 5, 2025 | EVMN Evommune, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +179,619 | $0.00 | $0 | 179,619 | Nov 7, 2025 |
Questions about Jeegar Pravinkumar Patel
Answered from the filings on this page, as of the latest one.
Is Jeegar Pravinkumar Patel buying or selling?
In the last 12 months Jeegar Pravinkumar Patel reported 0 open-market buys worth $0 and 2 open-market sells worth $413k on SEC Form 4; the latest was sold $33k of EVMN on Jun 22, 2026. Grants, option exercises and tax withholding are not counted.
How did Jeegar Pravinkumar Patel's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jeegar Pravinkumar Patel has 0.
Where does Jeegar Pravinkumar Patel file Form 4?
Jeegar Pravinkumar Patel has filed Form 4 at EVMN (Evommune, Inc.) as Chief Scientific Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.